Search Results
Your search for ,wAs matches 27466 pages
Showing 9601 - 9650Multiancestry Meta-analysis of Prostate Cancer Genetics
A research team has published findings from a study that brought together data from genomic prostate cancer studies. Including more than 200,000 men of European, African, Asian, and Hispanic ancestry from around the world, the study is reportedly the largest, most diverse genetic analysis ever...
Feasibility Study of Radical Cystectomy vs Intravesical BCG for High-Grade, Non–Muscle Invasive Bladder Cancer
As reported in the Journal of Clinical Oncology by Catto et al, the BRAVO-Feasibility study showed that recruitment of patients with high-grade, non–muscle invasive bladder cancer into a randomized trial comparing radical cystectomy vs intravesical bacillus Calmette-Guérin (BCG) proved difficult,...
SARS-CoV-2 Infection Among Patients in Italy Undergoing Active Cancer Treatment
In a retrospective study reported as a research letter in JAMA Oncology, Aschele et al found that the incidence of SARS-CoV-2 infection was 0.68% among a large population of patients receiving anticancer treatment in Italy over an approximately 3.5-month period in 2020. Study Details The study...
Use of a Novel CAR T-Cell Therapy in Pediatric and Adult Patients With Advanced B-Cell ALL
Pooled results of two phase I studies, reported in The Lancet by Benjamin et al, indicate that the genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor (CAR) T-cell product UCART19 is active and has a manageable toxicity profile in pediatric and adult patients with relapsed...
Surgical Intervention May Offer Survival Advantage for Certain Patients With Metastatic Breast Cancer
Surgery, in addition to treatments like chemotherapy and radiation therapy, may improve survival for certain patients with metastatic breast cancer. A research team studied nearly 13,000 patients with stage IV disease and found that those who had surgery in addition to other treatments had a...
Final Overall Survival Results of the IDEA Collaboration: 3 vs 6 Months of Adjuvant Chemotherapy for Stage III Colon Cancer
Thierry André, MD, and colleagues reported the prospective pooled analysis of six phase III trials in the IDEA collaboration in The Lancet Oncology. The analysis showed that noninferiority in overall survival for 3 vs 6 months of adjuvant chemotherapy was not established in patients with stage III...
Integrated Palliative and Oncology Care for Patients Receiving Treatment for AML
In a study reported in JAMA Oncology, Areej El-Jawahri, MD, and colleagues found that integrated palliative and oncology care was associated with better quality of life vs usual care among patients receiving treatment for acute myeloid leukemia (AML). The investigators stated, “Patients with AML...
Nivolumab Indication in Small Cell Lung Cancer Withdrawn in U.S. Market
On December 29, Bristol Myers Squibb issued the following statement on nivolumab’s small cell lung cancer (SCLC) indication in the United States. In 2018, nivolumab was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of patients with SCLC whose disease...
Patient-Reported Outcomes With Triplet Therapy for Newly Diagnosed Multiple Myeloma
In an analysis from the phase III MAIA trial reported in the Journal of Clinical Oncology, Perrot et al found that the combination of daratumumab, lenalidomide, and dexamethasone (D-Rd) was associated with better health-related quality-of-life outcomes vs lenalidomide and dexamethasone (Rd) in...
Global Burden of Cervical Cancer and Association With HIV
A research team has quantified the effects of infection with the human immunodeficiency virus (HIV) on the development of cervical cancer. Their results show that the risk of developing cervical cancer is six times higher in women who are infected with HIV, and that women who live in Southern and...
Study Clarifies Time-Dependent Effects of Oral Contraceptives on Risk of Ovarian, Endometrial, and Breast Cancers
A comprehensive study involving more than 250,000 women showed that oral contraceptive use may be protective against the development of ovarian and endometrial cancers, but the effect on lifetime risk of breast cancer is more limited. The protective effect on ovarian and endometrial cancers was...
Ganglioside Vaccine Plus β-Glucan for Patients With High-Risk Neuroblastoma and Prior Disease Progression
In a single-institution phase II study reported in the Journal of Clinical Oncology, Cheung et al found that a subcutaneous ganglioside G2/G3 vaccine plus oral β-glucan produced antibody responses in patients with high-risk neuroblastoma, with higher anti–GD2-IgG1 titers being associated with...
Left Anterior Descending Coronary Artery Radiation Exposure, Cardiac Events, and Mortality in NSCLC
In a retrospective cohort analysis reported in JAMA Oncology, Atkins et al identified a volume (V, percent) of exposure of the left anterior descending (LAD) coronary artery to a radiation dose (V15 Gy ≥10%) that is an independent risk factor for major adverse cardiac events and all-cause mortality ...
Neoadjuvant Chemotherapy and Overall Survival in Metastatic Endometrial Cancer
In a National Cancer Database analysis reported in JAMA Network Open, Tobias et al found that receipt of neoadjuvant chemotherapy was associated with improved short-term but not long-term survival vs primary debulking surgery in patients with metastatic endometrial cancer. As stated by the...
FDA Issues Emergency Use Authorization for Second COVID-19 Vaccine
On December 18, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the second vaccine for the prevention of COVID-19 caused by SARS-CoV-2. The emergency use authorization allows the Moderna COVID-19 Vaccine to be distributed in the United States for use in...
Addition of First-Line Pembrolizumab to Chemotherapy in Metastatic Triple-Negative Breast Cancer: KEYNOTE-355
As reported in The Lancet by Javier Cortes, MD, and colleagues, the phase III KEYNOTE-355 trial has shown that the addition of pembrolizumab to chemotherapy improved progression-free survival among previously untreated patients with locally recurrent inoperable or metastatic triple-negative breast...
Gemogenovatucel-T Maintenance in Stage III/IV Ovarian Cancer
In the phase IIb VITAL trial reported in The Lancet Oncology, Rocconi et al found that front-line maintenance with the autologous tumor cell vaccine gemogenovatucel-T did not improve recurrence-free survival vs placebo in patients with stage III/IV ovarian cancer in clinical complete response after ...
Risk of COVID-19 Infection in Patients With Cancer: Effect of Time of Diagnosis and Race
In a study reported in JAMA Oncology, Wang et al found that patients with cancer were at a greater risk of being infected with COVID-19 and having worse outcomes vs patients without cancer. Risk was greatest among patients with a more recent diagnosis and was even further exacerbated among Black...
Reducing Disparities in Cancer Care for Sexual and Gender Minority Patients
Although efforts have been made by various medical societies, including ASCO, over the past decade to address the needs of sexual and gender minorities in the cancer care setting, research shows that lesbian, gay, bisexual, transgender, and queer/questioning (LGBTQ) patients continue to face...
Effect of the COVID-19 Pandemic on Lung Cancer Screening
Reporting on how deferred care worsened outcomes for patients with lung cancer when the COVID-19 pandemic first surged in the spring of 2020, Robert M. Van Haren, MD, MSPH, FACS, and colleagues explained that they have identified a framework that could help people with serious health conditions...
Risk for Osteonecrosis of the Jaw After Treatment With Zoledronic Acid for Metastatic Bone Disease
In an observational cohort study reported in JAMA Oncology, Catherine H. Van Poznak, MD, FASCO, and colleagues found that the 3-year incidence of osteonecrosis of the jaw was 2.8% among patients with cancer receiving zoledronic acid for metastatic bone disease. Shorter dosing interval, fewer teeth, ...
The Heart of Catherine Handy Marshall, MD, MPH’s Work
In 2017, Women Who Conquer Cancer (WWCC) awarded Catherine Handy Marshall, MD, MPH, a Conquer Cancer Young Investigator Award (YIA) grant to explore the impact of cardiovascular disease risk factors on cancer outcomes. Three years after receiving the WWCC YIA, Dr. Handy Marshall is pursuing...
Increase Your Knowledge and Practice of Cultural Competence With ASCO eLearning Course Collection
“Equity: Every Patient. Every Day. Everywhere” was selected by 2020–2021 ASCO President Lori J. Pierce, MD, FASTRO, FASCO, as the theme for her presidential term. As oncology care providers work to put this theme into practice, they can find support in ASCO eLearning’s new Cultural Literacy course...
Intensity of Active Surveillance in Patients With Rectal Cancer Managed With a Watch-and-Wait Approach
In a study reported in The Lancet Oncology, Fernandez et al found high rates of conditional recurrence-free survival during watch-and-wait surveillance among patients with rectal cancer who maintained clinical complete response to neoadjuvant chemotherapy for 1, 3, or 5 years. Study Details In the...
Pembrolizumab Plus Chemotherapy for Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer
On November 13, 2020, pembrolizumab (Keytruda) was granted accelerated approval by the U.S. Food and Drug Administration (FDA) for use in combination with chemotherapy for patients with locally recurrent unresectable or metastatic triple-negative breast cancer with tumors expressing PD-L1 (Combined ...
Roswell Park Experts Named to Highly Cited Researchers List
Roswell Park Comprehensive Cancer Center’s Igor Puzanov, MD, MSCI, FACP, Andrew Hyland, PhD, and Maciej Goniewicz, PhD, PharmD, have all recently been recognized as global scientific pioneers on Clarivate Plc’s Highly Cited Researchers list for 2020. The list recognizes researchers who have...
Addition of Capivasertib to Docetaxel/Prednisolone in Patients With Metastatic Castration-Resistant Prostate Cancer
In the phase II ProCAID study reported in the Journal of Clinical Oncology, Crabb et al found that the addition of the pan-AKT inhibitor capivasertib to docetaxel and prednisolone did not significantly improve progression-free survival in patients with metastatic castration-resistant prostate...
Anthony Fauci, MD, Encourages Patients With Cancer to Receive COVID-19 Vaccine
The American Society of Hematology (ASH) President Stephanie Lee, MD, MPH, sat down with Anthony Fauci, MD, Director of the National Institutes of Allergy and Infectious Diseases (NIAID) and medical advisor to President-Elect Joseph Biden, for a virtual fireside chat about COVID-19 and cancer at...
Expert Point of View: Cathy Eng, MD
Cathy Eng, MD, the David H. Johnson Chair in Surgical and Medical Oncology, Co-Leader of the Gastrointestinal (GI) Cancer Research Program, and Co-Director of GI Oncology at Vanderbilt-Ingram Cancer Center in Nashville, as well as Vice Chair of the SWOG GI Committee, said she found the study’s...
Study Reports Highly Skilled Surgeons Significantly Reduce Death From Colon Cancer
To improve long-term survival odds, individuals with early-stage colon cancer should have their surgery performed by highly skilled surgeons. In a study that used video assessment, surgeons with highly ranked skills gave their patients a 69% lower risk of dying at 5 years as compared with their...
John Ryan, JD, Named Senior Vice President and General Counsel at Dana-Farber Cancer Institute
Dana-Farber Cancer Institute has appointed John Ryan, JD, as its Senior Vice President, General Counsel, and Chief Governance Officer. Mr. Ryan has extensive expertise representing health-care and life sciences organizations in public company and nonprofit settings. He has managed a wide range of...
Pembrolizumab Improves Progression-Free Survival vs Chemotherapy in First-Line Treatment of Microsatellite Instability–High Advanced Colorectal Cancer
As reported in The New England Journal of Medicine by Thierry André, MD, of Sorbonne Université and Hôpital Saint Antoine, Paris, and colleagues, the second interim analysis of the phase III KEYNOTE-177 trial has shown significantly prolonged progression-free survival with pembrolizumab vs...
Chronicling a Family’s History of Cancer
Cancer has been an intimate part of Nancy Borowick’s life since her mother, Laurel, was diagnosed with breast cancer in 1997, when Nancy was 12. She began photographing her mother’s journey with the disease after the cancer recurred in 2009 for her final project for the Documentary Photography and ...
Selected ASH Abstracts on Novel Treatments of Polycythemia Vera
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are three abstracts selected from the meeting proceedings focusing on novel therapies for polycythemia vera. For full details of these study...
FDA Approves Adjuvant Osimertinib for EGFR-Mutated NSCLC
On December 18, the U.S. Food and Drug Administration (FDA) approved osimertinib (Tagrisso) for adjuvant therapy after tumor resection in patients with non–small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as...
Sue S. Yom, MD, PhD, FASTRO, Named Editor-in-Chief of ASTRO’s Red Journal
The American Society for Radiation Oncology (ASTRO) announced the appointment of Sue S. Yom, MD, PhD, FASTRO, as Editor-in-Chief of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), ASTRO’s flagship scientific journal. Dr. Yom, who is Vice Chair and Distinguished...
2020 Basser Global Prize Awarded to Bella Kaufman, MD, of Israel’s Sheba Medical Center
The Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania recently announced Bella Kaufman, MD, of the Sheba Medical Center in Tel-Hashomer, Israel, as the recipient of the eighth annual Basser Global Prize. Dr. Kaufman is Director of the Breast Oncology Institute,...
ASH Recognizes Choosing Wisely Champions at Annual Meeting & Exposition
The American Society of Hematology (ASH) recognized three Choosing Wisely Champions, practitioners working to tackle overuse of hematology tests and treatments, at the all-virtual 2020 ASH Annual Meeting & Exposition. Choosing Wisely, a program of the ABIM Foundation and Consumer Reports, aims...
European Experts Tackle HPV-Related Cancers
The prevention of infection with the human papillomavirus (HPV), and its related cancers, has become a focus of the European Cancer Organisation. At the group’s 2020 European Cancer Summit, held virtually, members of the organization’s HPV Action Network convened with other experts to share...
Panel on Global Cancer Control Looks for Ways Forward in a War That’s Proving Hard to Win
Are we winning the war on cancer? It’s not so clear, especially with COVID-19 poised to erase recent gains, panelists said at a session on global cancer control at the 2020 European Cancer Summit, which was sponsored by the European Cancer Organisation. “We know what we have to do. My question is...
Addressing Inequality in Cancer Care on a Global Scale
It has become a familiar theme of late: Inequities exist in all aspects of cancer care. Although study after study documents problems with access to care and poorer cancer outcomes among underrepresented groups, less is heard about organized efforts to address these issues. This critical topic was...
IU Simon Researcher Receives $1.3 Million Grant to Improve Breast Cancer Treatment for Black Women
Harikrishna Nakshatri, PhD, who is identifying the unique biology that may make Black women more susceptible to aggressive breast cancer, received a $1.3 million grant from the Department of Defense–Congressionally Directed Medical Research Program’s breast cancer research program. Dr. -Nakshatri...
Intratumoral Injections May Boost Neoadjuvant Response in Resectable Melanoma
Studies reported at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting, which was held virtually, showed promise for the use of intratumoral injections of novel immunotherapies in treating advanced, resectable melanoma. In the 3-year interim analysis of a global phase II randomized...
Novel Combination Under Study in First-Line Treatment of Metastatic Melanoma
A first-line regimen combining the novel interleukin-2 (Il-2) agonist bempegaldesleukin (NKTR-214) with nivolumab showed encouraging clinical activity in patients with metastatic melanoma in the phase I/II PIVOT-02 trial, according to a presentation during the 2020 Annual Meeting of the Society for ...
Sexual Health: An Issue for Many Survivors of Cancer
Sexual dysfunction is prevalent among cancer survivors—and rarely addressed—according to data presented during the 2020 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 A survey of cancer survivors has found that nearly 9 out of 10 respondents reported some change after cancer...
Expert Point of View: Laura Dawson, MD
Laura Dawson, MD, Professor of Radiation Oncology at the University of Toronto and Princess Margaret Cancer Centre, viewed these initial study results as “a strong signal with high promise.” “Radiation therapy improves local control and delays local disease progression in patients with pancreatic...
Novel Radiomodulation Approach With Dismutase Mimetic Plus SBRT in Resectable Pancreatic Cancer
Pancreatic cancer is one of the most aggressive, lethal malignancies, and life-extending treatments represent a critical unmet need. A pilot study suggests a potential way forward for patients with nonmetastatic unresectable or borderline resectable pancreatic cancer may be a combination of...
Pralsetinib for RET-Altered Thyroid Cancers
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On December 1, 2020, pralsetinib (Gavreto) was granted...
CTC Enumeration Predicts Survival Early in Treatment of Metastatic Breast Cancer
The number of circulating tumor cells (CTCs) assessed at baseline and at about 1 month after cancer-directed treatment was strongly associated with overall survival in patients with metastatic breast cancer, according to a large retrospective pooled analysis reported at the 2020 San Antonio Breast...
Edith Mitchell, MD, Elected to Fellowship in the Royal College of Physicians of London
Edith P. Mitchell, MD, FACP, FCPP, FRCP, Associate Director for Diversity Affairs at the Sidney Kimmel Cancer Center–Jefferson Health, has been recognized as a fellow of the Royal College of Physicians of London (RCP). The RCP was founded in 1518 by a Royal Charter from King Henry VIII. RCP...
